25.04.2024,
3663 Zeichen
Brussels and Prague (ots/PRNewswire) - Zentiva, a Pan-European
pharmaceutical company, joined the inaugural launch of the EU's
Critical Medicines Alliance, held on April 24-25 in Brussels. This
significant event, organized by DG HERA and the Belgian Presidency,
convened leaders from across the healthcare industry to address the
challenges of medicine supply resilience in the European Union.
Zentiva's CEO, Steffen Saltofte, and representatives from the
pharmaceutical industry and Medicines for Europe, the Generics
association, engaged with EU Health Ministers and discussed
actionable strategies to enhance the availability and accessibility
of critical medicines throughout Europe.
Steffen Saltofte: "Our participation in the Alliance underscores our
commitment. Together, we need to ensure that essential medicines are
accessible to all people who depend on them. As generic medicines
represent 70% of treatment volume in Europe and constitute 9 out of
10 products on the critical medicines list, our role is crucial in
maintaining the continuity of healthcare services across the
continent."
DG HERA presented a Vulnerability Assessment performed on a tranche
of 11 chosen critical medicines, selected from a broader list of over
200 critical medicines. Zentiva has seriously engaged in this
assessment and believes it will be instrumental in addressing future
medicine shortages. The discussion highlighted the need for increased
manufacturing resilience.
Steffen Saltofte: "We believe that this assessment and our diligent
efforts will lead to comprehensive solutions for shortages, support
the European production of medicines, and ensure that the focus
remains on substantive outcomes rather than merely increasing
administrative burdens and regulations."
Discussions also covered strategies for preventing medicine
shortages, enhancing EU manufacturing competitiveness, and ensuring
equitable access across member states.
Zentiva shared insights from its extensive experience in producing
high-quality and affordable medicines at its manufacturing sites in
the Czech Republic and in Romania that are marketed in more than 30
countries. The team of 5.000 people is devoted to supporting the EU's
vision of building a robust and sustainable healthcare system, that
ensures high-quality, accessible pharmaceutical solutions to all
people who depend on them.
About Zentiva
Zentiva is a Pan-European Company developing, manufacturing and
providing high-quality and affordable medicines to more than 100
million people in Europe. Zentiva has 4 wholly owned manufacturing
sites and a broad network of external manufacturing partners to
ensure supply security. We offer solutions in key therapeutical areas
like Cardiology & Circulation, Diabetes, Oncology, Respiratory, CNS,
and focus on expanding our portfolio in self-care. The company is
Private Equity owned, delivering sustainable double-digit growth,
with an ambitious 5-year plan for further strong growth across
Europe.
We are a team of 5.000 unique talents bonded together by our
responsibility to ensure the supply of high-quality and affordable
medicines to people who depend on them every day. We want Zentiva to
be a great place to work, where everyone feels welcomed and
appreciated, and can be their authentic selves contributing to the
best of their ability. We provide health and wellbeing to all
generations.
www.zentiva.com
Photo -
https://mma.prnewswire.com/media/2397673/Zentiva_Critical...
lliance.jpg
View original content to download
multimedia:https://www.prnewswire.co.uk/news-releases/zentiva-joins-t
he-critical-medicines-alliance-to-enhance-eu-medicine-supply-30212756
1.html
Digital press kit:
http://www.ots.at/pressemappe/PR132270/aom
BSN Podcasts
Christian Drastil: Wiener Börse Plausch
SportWoche Podcast #107: Kave Atefie, Co-Founder gesund.co.at, Maradonas Balljunge, Rocky-Box-Double, BB King Vorgruppe
Aktien auf dem Radar:Palfinger, Immofinanz, Kapsch TrafficCom, Flughafen Wien, EuroTeleSites AG, Addiko Bank, Rosgix, Telekom Austria, RBI, SBO, Uniqa, ams-Osram, Oberbank AG Stamm, Agrana, Amag, CA Immo, Erste Group, EVN, FACC, OMV, Österreichische Post, VIG, Wienerberger, Warimpex, Henkel, Apple, Amgen, Deutsche Post, Vonovia SE, Beiersdorf, Münchener Rück.
Polytec
Die Polytec Group ist ein Entwickler und Hersteller von hochwertigen Kunststoffteilen und ist mit 26 Standorten und über 4.500 Mitarbeitern weltweit aktiv. Das österreichische Unternehmen zählt renommierte Weltmarken der Automobilindustrie zu seinen Kunden.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER